Journal
BLOOD
Volume 107, Issue 8, Pages 3279-3287Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2005-08-3087
Keywords
-
Categories
Ask authors/readers for more resources
Although targeting the BCR-ABL tyrosine kinase activity by imatinib mesylate has rapidly become first-line therapy, in chronic myelold leukemia (CIVIL), drug resistance suggests that combination therapy directed to a complementing target may significantly improve treatment results. To identify such potential targets, we used lentivirus-mediated RNA interference (RNAi) as a tool for functional genomics in cell lines as well as primary normal and CIVIL CD34(+) cells. In a conditional cell culture model, we demonstrate that RNAi-mediated reduction of SHIP2, STAT5, and Gab2 protein expression inhibits BCR-ABL-dependent but not cytokine-dependent proliferation in a dose-dependent manner. Similarly, colony formation of purified primary CIVIL but not of normal CD34(+) colony-forming cells is specifically reduced by inhibition of SHP2, STAT5, and Gab2 expression, respectively. In addition, coexpression of both anti-BCR-ABL and anti-SHIP2 shIRNAs from a single lentiviral vector induces stronger inhibition of colony formation as compared to either shRNA alone. The data indicate that BCR-ABL expression may affect the function of normal signaling molecules. Targeting these molecules may harbor significant therapeutic potential for the treatment of patients with CIVIL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available